Advertisement
Organisation › Details
Epizyme Inc. (Nasdaq: EPZM)
Epizyme is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company, headquartered in Cambridge, Massachusetts in the U.S., is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. *
Start | 2007-01-01 established | |
Industry | epigenetics / epigenomics | |
Industry 2 | small-molecule drug | |
Region | Cambridge, MA | |
Country | United States (USA) | |
Street | 400 Technology Square 4th Floor | |
City | 02139 Cambridge, MA | |
Tel | +1-617-229-5872 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Ipsen S.A.. (6/27/22). "Press Release: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology". Paris & Cambridge, MA. | ||
Record changed: 2023-07-10 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top